Credit Suisse’s Alnylam Pharmaceuticals ALNY Stock Holding History

Credit Suisse’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-40,600	Closed	-$6.88M	–	4377
2021 Q2	$6.88M	Buy	40,600 +8,900	+28%	+$1.3M	﹤0.01%	1824
2021 Q1	$4.48M	Buy	31,700 +29,900	+1,661%	+$4.5M	﹤0.01%	2164
2020 Q4	$234K	Hold	1,800	–	–	﹤0.01%	4052
2020 Q3	$262K	Buy	+1,800	New	+$256K	﹤0.01%	3719
2020 Q2	–	Sell	-75,000	Closed	-$8.16M	–	3939
2020 Q1	$8.16M	Buy	+75,000	New	+$8.66M	0.01%	1273
2019 Q1	–	Sell	-351,700	Closed	-$25.6M	–	3971
2018 Q4	$25.6M	Buy	+351,700	New	+$27.1M	0.03%	656

Other funds holding ALNY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse's ALNY Position: Q1 2024 in Review

Credit Suisse reduced its Alnylam Pharmaceuticals (ALNY) stake by 26% in Q1 2024, selling an estimated $7.78M and leaving 129,346 shares worth $19.3M. The position accounts for 0.02% of the portfolio, ranked #642.

Credit Suisse first reported a position in ALNY in Q2 2013 and has held it in 44 quarters since. The position peaked at $37.2M in Q1 2018. 498 funds tracked by Wall St. Rank hold ALNY as of Q1 2024.

Credit Suisse held 129,346 shares of Alnylam Pharmaceuticals worth $19.3M as of Q1 2024.
Credit Suisse sold 46,630 Alnylam Pharmaceuticals shares in Q1 2024, an estimated $7.78M.
Alnylam Pharmaceuticals made up 0.02% of Credit Suisse's portfolio in Q1 2024, its #642 holding.
Credit Suisse first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 44 quarters since.
Credit Suisse's Alnylam Pharmaceuticals position peaked at $37.2M in Q1 2018.
498 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.